Cart
sales@molnova.com
N-Hydroxypipecolic acid
CAS No. 115819-92-6
N-Hydroxypipecolic acid( 1-Hydroxy-2-piperidinecarboxylic acid | NHP )
Catalog No. M23336 CAS No. 115819-92-6
N-Hydroxypipecolic acid is a plant metabolite and a systemic acquired resistance (SAR) regulator.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 48 | In Stock |
|
| 5MG | 77 | In Stock |
|
| 10MG | 138 | In Stock |
|
| 50MG | 262 | In Stock |
|
| 100MG | 337 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameN-Hydroxypipecolic acid
-
NoteResearch use only, not for human use.
-
Brief DescriptionN-Hydroxypipecolic acid is a plant metabolite and a systemic acquired resistance (SAR) regulator.
-
DescriptionN-Hydroxypipecolic acid is a plant metabolite and a systemic acquired resistance (SAR) regulator.
-
In Vitro——
-
In Vivo——
-
Synonyms1-Hydroxy-2-piperidinecarboxylic acid | NHP
-
PathwayOthers
-
TargetOther Targets
-
RecptorSAR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number115819-92-6
-
Formula Weight145.16
-
Molecular FormulaC6H11NO3
-
Purity>98% (HPLC)
-
SolubilityDMSO:83.33 mg/mL (574.06 mM; Need ultrasonic)
-
SMILESO=C(C1N(O)CCCC1)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Hartmann M, et al. N-hydroxypipecolic acid and salicylic acid: a metabolic duo for systemic acquired resistance. Curr Opin Plant Biol. 2019 Aug;50:44-58.
molnova catalog
related products
-
5-Methoxysuberenone
5-Methoxysuberenone is a chemical constituent of the root bark of Toddalia asiatica (L.) Lam. (T. aculeata Pers.), Rutaceae.
-
3-Methyl-2-oxobutano...
alpha-Ketoisovaleric acid is an abnormal metabolite that arises from the incomplete breakdown of branched-chain amino acids. alpha-Ketoisovaleric acid is a neurotoxin an acidogen and a metabotoxin.
-
Tremelimumab
Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and lung cancer.
